NY-ESO-1 T-Cell Immunotherapy for Recurrent or Refractory Ovarian Cancer: Clinical Effectiveness


( Last Updated : November 15, 2018)
Project Line:
Reference List
Project Sub Line:
Reference List
Project Number:
RA0989-000

Details


Question


  1. What is the clinical effectiveness of NY-ESO T-cell immunotherapy in adults with recurrent or refractory ovarian cancer?


Key Message

No relevant literature was identified regarding the clinical effectiveness of NY-ESO T-cell immunotherapy in adults with recurrent or refractory ovarian cancer.